Podcasts about Diabetes

Episode 4136 │ June 2, 2026 Dr. Joel Wallach reveals why obesity, diabetes, and metabolic syndrome are nutritional deficiency diseases — and why medicine profits from keeping you sick. In this featured presentation, veterinarian and physician Dr. Joel Wallach delivers his landmark Hell's Kitchen talk — a systematic breakdown of why obesity, type 2 diabetes, and metabolic syndrome are not genetic failures or lifestyle weaknesses, but predictable outcomes of mineral-depleted food and a medical system with no financial incentive to cure what it can manage. Wallach draws on four decades of animal and human research, including 17,500 autopsies across 454 species, to show that the same nutritional formulas that eliminated disease in livestock apply directly to human metabolism. He traces the collapse of dietary minerals to the modern electric kitchen, documents USDA data showing catastrophic nutrient loss in American food from 1975 to 2004, and explains the suppressed 1957 discovery that adult onset type 2 diabetes can be prevented and reversed with two trace minerals. He also dismantles the conventional warnings on salt, cholesterol, eggs, and exercise — and profiles the common traits of people who live well past 100. What is Hell's Kitchen — and how did the modern electric stove trigger a cascade of metabolic disease in America? What causes obesity and type 2 diabetes at the nutritional level, and why have doctors ignored the cure since 1957? Why do the longest-lived people on earth share low carbohydrate intake and daily mineral replenishment? Does salt cause high blood pressure — what does the government's own sodium study actually conclude? Why have professional athletes never lived to 100, while sedentary people routinely do? BardsFM is a daily independent podcast covering faith, liberty, history, and information warfare. Hosted by Scott Kesterson — combat veteran, documentary filmmaker, and rancher. Over 4,100 episodes and 50 million lifetime downloads. New episodes every weekday. bards.fm #BardsFM_HealthAndWellness #WholeBodyHealth #Nutrification Bards Nation Health Store: www.bardsnationhealth.com MYPillow promo code: BARDS >> Go to https://www.mypillow.com/bards and use the promo code BARDS or... Call 1-800-975-2939.  EMPShield protect your vehicles and home. Promo code BARDS: Click here Treadlite Broadforks...best garden tool EVER. Promo code BARDS26: TreadliteBroadforks.com EnviroKlenz Air Purification, promo code BARDS to save 10%: www.enviroklenz.com Morning Intro Music Provided by Brian Kahanek: www.briankahanek.com Founders Bible 20% discount code: BARDS >>> TheFoundersBible.com Windblown Media 20% Discount with promo code BARDS: windblownmedia.com White Oak Pastures Grassfed Meats, Get $20 off any order $150 or more. Promo Code BARDS: www.whiteoakpastures.com/BARDS Mission Darkness Faraday Bags and RF Shielding. Promo code BARDS: Click here If you wish to support this podcast directly you can donate here... DONATE: Click here Mailing Address: Xpedition Cafe, LLC Attn. Scott Kesterson 591 E Central Ave, #740 Sutherlin, OR  97479

866. The market is suddenly full of products claiming to prevent or even reverse gray hair — not by dyeing it, but by actually changing what's happening inside the hair follicle. Some of these serums, supplements, and "anti-gray systems" are backed by genuinely interesting science. Others are getting way ahead of the evidence. Today, Monica breaks down the biology of why hair goes gray, what ingredients show the most promise (and for whom), and which products are banking more on your hope than on clinical proof. Nutrition Diva is a Quick and Dirty Tips podcast, hosted by Monica Reinegal.New to Nutrition Diva? Check out our special Spotify playlist for a collection of the best episodes curated by our team and Monica herself! We've also curated some great playlists on specific episode topics including Staying Strong as We Age, Diabetes, Weight Loss That Lasts and Gut Health! Also, find a playlist of our bone health series, Stronger Bones at Every Age. Have a question for Nutrition Diva? Email: nutrition@quickanddirtytips.comFind Monica at wellnessworkshere.comDiscover more from Nutrition Diva:Facebook LinkedInNewsletterTranscripts available at QuickandDirtyTips.com. Hosted on Acast. See acast.com/privacy for more information.

During his 36-year career as a general and trauma surgeon, Dr. Harry Black was diagnosed with high-grade prostate cancer in 2021 — and later, metastatic cancer in 2023. What he learned about the metabolic root causes of chronic disease during those years changed everything he thought he knew about medicine.He retired in January 2026 and founded the Sunrise Institute for Health, Wellness, and Longevity. Now he shares how modern Western medicine can learn from its holistic, herbalist roots — to cure underlying disease processes rather than treat symptoms.Join host Khudania Ajay (KAJ) as they explore the root-cause approach that reversed his Type 2 Diabetes and helped him treat his cancer, why organized medicine misses the metabolic origins of chronic disease, and how patients can take control of their health alongside their physicians.Support independent journalism at https://kajmasterclass.com

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

This week, primary care doctors Mark Ebell, Kate Rowland, Henry Barry and Gary Ferenchick discuss four new studies: whether water is better than diet drinks in diabetes, a new RCT of Paxlovid for COVID in contemporary patients, to switch or not to switch antiplatelet agents after a stroke, and the latest AHA 2026 dietary advice for heart health.Drinks for diabetes: ttps://pubmed.ncbi.nlm.nih.gov/41369640/ Antiplatelet agents after stroke on aspirin: https://pubmed.ncbi.nlm.nih.gov/41347302/ New Paxlovid trial: https://pubmed.ncbi.nlm.nih.gov/42019019/ AHA 2026 dietary guidance: https://pubmed.ncbi.nlm.nih.gov/41914202/

Welcome to the latest episode (June 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Update: Shah S, et al. "Food Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort Diabetes Care. 2026;49(6):1067–1077. doi.org/10.2337/dc25-2727 Hespanhol L, et al. "Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis." Diabetes Care. 2026;49(6):1134–1143. doi.org/10.2337/dc25-2435 Tatum K, et al. "Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer." JAMA. Published Online: May 11, 2026 2026;9;(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133 Winkler C, et al. "Screening Children for Early-Stage Type 1 Diabetes." JAMA. Published Online: May 21, 2026 doi:10.1001/jama.2026.6085 Würtz Yazdanfard P, Kosjerina V, Wood-Kurland H et al. "Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018–2024)" Lancet. Volume 66, 101716, July 2026. doi:10.1016/j.lanepe.2026.101716 Horn D, Aronne L, Wharton S et al. "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial." Lancet. Published online May 12, 2026. doi:10.1016/S0140-6736(26)00656-2 Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In this episode, Coach Ken and Graham tackle one of the most fascinating and controversial questions in the diabetes world:What will happen first—a cure for Type 1 diabetes or a way to prevent it altogether?The conversation begins with a discussion around continuous glucose monitors, the barriers to bringing new diabetes technology to market, and why FDA approval plays such a significant role in innovation and accessibility.From there, Ken and Graham zoom out to examine diabetes on a global scale. They explore the challenges people with diabetes face in developing countries, the realities of insulin access, and whether advanced technology like CGMs should be prioritized when many people still struggle to obtain life-saving insulin.The discussion then shifts into the future of Type 1 diabetes research, including Teplizumab (Tzield), immunotherapy, stem cell research, autoimmune triggers, and the ongoing debate between prevention and cure.Along the way, Ken shares his perspective on the role that lifestyle factors—including stress, sleep, nutrition, exercise, and overall health—may play in autoimmune conditions, while Graham challenges the conversation by exploring whether vaccines, immunotherapy, or preventative treatments could eventually become the standard approach.This episode is an honest discussion about innovation, skepticism, hope, and the future of diabetes care.

A retrospective comparison of two state-funded smartphone-based contingency management programs with different incentives  Drug and Alcohol Dependence This retrospective study compared outcomes for patients with stimulant use disorder enrolled in a smartphone-based contingency management program based on the amount of total incentives possible, either $75 (“low-value”) or $599 (“moderate-value”). The low-value program was based in New Jersey, funded through SAMHSA (which limited reimbursement to $75/patient at the time of implementation, which has since been increased), and rewarded completing drug testing, attending counseling visits, and completing CBT modules rather than abstinence over 16 weeks. The moderate-value program was funded by West Virginia's Medicaid managed care organizations, lasted up to 26 weeks, and largely rewarded negative drug screening results, with additional rewards for counseling and CBT modules. Patients in the moderate-value program submitted significantly higher rates of negative substance tests (36%, with an average of 3.2 negative tests) compared to those in the low-value group (24.7%, with an average of 24.8 negative tests).   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

DR. JASON SHUMARD is a Functional Medicine practitioner with more than two decades helping people with Type 2 Diabetes and insulin resistance find true answers, especially those who feel confused by conventional approaches. Rather than seeing diabetes as just about numbers, he focuses on lab-based, root-cause investigation into why blood sugar rises and disease progresses, going far deeper than "eat less sugar" or "more meds." Dr. Shumard makes metabolic and cellular health understandable for everyone, empowering individuals to take the reins on their own health journeys. His passion is deeply personal, stemming from losing his mother to diabetes complications, which drives his mission to transform patient experience from one of fear to informed action  www.drshumard.com  

EVEN MORE about this episode!What if the symptoms you're experiencing aren't the real problem—but clues pointing to a deeper root cause?In this episode, Julie Ryan performs live intuitive scans and energetic healings for callers around the world, uncovering hidden factors behind chronic health challenges, emotional struggles, and spiritual questions.From thyroid concerns in Greece and diabetes complications in Missouri to chronic anemia in England and a hearing-related tumor in California, Julie uses her medical intuitive abilities to identify energetic and physical imbalances while providing practical wellness guidance.You'll also witness powerful spirit communication, emotional healing after loss, support for a child recovering from brain surgeries, insights for a puppy experiencing seizures, and guidance for a caller hoping to avoid a second shoulder surgery. Along the way, Julie demonstrates how physical symptoms, emotional experiences, and spiritual growth are often more connected than we realize.Whether you're seeking healing, hope, or simply curious about what's possible when intuition meets wellness, this episode offers powerful insights into the hidden causes behind many of life's most challenging situations.Episode Chapters:(0:00:00) - Welcome and Thyroid/Pineal Gland Scan: Maria from Greece(0:05:03) - Type 2 Diabetes, Mounjaro, and the Keto Alternative: Connie from Missouri(0:09:05) - Schwannoma Tumor and Hearing Loss: Karen from California(0:19:58) - Sleep, Hormones, and BEAM Minerals: Judy from Florida(0:24:34) - Spirit Connection and Intuition: Sahar from Sweden(0:33:33) - Shoulder Surgery and Physical Therapy: Ryan from North Carolina(0:44:19) - Free Class Giveaway Winner Announced(0:47:29) - Puppy Seizures and Vaccine Reactions: Jessica from Maine(0:37:28) - Processing Grief: Ana and Her Father Antonio(0:53:36) - Chronic Anemia and Hormonal Healing: Anastasia from England(0:57:38) - Post-Brain Surgery Recovery: Karen and Her Son Kristoff from Phoenix➡️ Subscribe to Ask Julie Ryan YouTube➡️ Julie's Intuitive Trainings✏️ Ask Julie a Question!

In this special edition of Diabetes Core Update, Neil Skolnik discusses PATHWEIGH, a novel obesity care process for primary care clinicians which has demonstrated a decrease in population weight gain. This special episode is sponsored with support from Lilly. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Leigh Perreault, MD, Professor of Pedicine in the Division of Endocrinology, Metabolism and Diabetes, at the University of Colorado Denver School of Medicine, Aurora, CO Reference: Perreault, L., Pan, Q., Rodriguez, C. et al. Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial. Nat Med 32, 645–652 (2026). 

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In this episode, Coach Ken and Graham dive into one of the biggest disconnects in diabetes management: the difference between medical guidance and lived experience.The conversation explores why so many people with diabetes feel stuck between short endocrinology appointments and the reality of managing blood sugars every single day. Ken breaks down why endocrinologists are an incredibly important part of the diabetes care team—but also why they should be viewed as a tool, not the entire answer.Together, Ken and Graham unpack:the limitations of 15–20 minute appointmentswhy doctors can't fully understand your day-to-day diabetes decisionshow real confidence is built between appointmentsand why people living with diabetes must eventually learn to trust themselves and their own lived experiencesThe discussion also touches on information overload, the internet's influence on health education, movement and insulin sensitivity, and why activities like golf, sports, and social connection can play a much larger role in overall health than people realize.This episode is a powerful reminder that diabetes management doesn't happen inside the doctor's office—it happens in the real world, every single day.

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In this episode, Coach Ken sits down with Ryan Bash for a powerful conversation about what it's really like growing up and navigating school with Type 1 diabetes.Ryan shares his experience being diagnosed at a young age and how diabetes has shaped the way he approaches problem-solving, engineering, school, sports, and self-advocacy. What starts as a conversation around math, measurement, and hands-on learning evolves into a much deeper discussion about the real-life challenges kids with diabetes face every single day in school systems that often don't fully understand the condition.Together, Ken and Ryan unpack:how diabetes develops problem-solving skillswhy “if this, then this” thinking becomes second naturethe impact of highs and lows during tests and classnavigating 504 plans and accommodationsdealing with substitute teachers and school policiesadvocating for yourself when adults don't understand diabetesand why blood sugar numbers should never define self-worthRyan also shares several frustrating experiences with teachers and school staff who ignored or misunderstood his diabetes accommodations, leading to a powerful conversation around communication, confidence, and self-advocacy.

CDMX transparentará obras rumbo al Mundial 2026Especialistas llaman a prevenir infartos cerebralesVenezuela recibe vuelo con migrantes deportados de EE.UU. Más información en nuestro Podcast#grc

Don Muchow has lived with Type 1 Diabetes for more than 50 years (@t1determined).But his story isn't just about Diabetes.At 42 years old, Don was overweight, struggling with his health, and already experiencing serious Diabetic complications before making a decision that completely changed the direction of his life.What started with exercise and small lifestyle changes eventually led to Ironman races, ultra-marathons, marathon swims, 200-mile cycling events, and even becoming the first and only known person with Type 1 Diabetes to run from Disneyland to Walt Disney World… covering 2,845 miles across America.In this episode, we talk about:Living with Type 1 Diabetes for over five decades.Overcoming complications later in life.Endurance training and blood sugar management.Fear around exercise and hypos.Aging with Type 1 Diabetes.Mindset, resilience, and consistency.What's actually possible with Diabetes long term.This is an incredibly honest, motivating, and practical conversation for anyone living with Type 1 Diabetes, especially those who feel like it may be “too late” to change their health.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

Alerta por diabetes infantil en CDMX Más de 48 mil trámites gratuitos en EdomexÉbola deja 238 muertes sospechosas en RDCMás información en nuestro podcast#grc

865. The USDA unveiled the 2025–2030 Dietary Guidelines for Americans, and the "Inverted Pyramid" has been sparking a lot of discussion. After a decade of MyPlate, why is the government returning to a pyramid visual—and why is it upside down?In this episode, Monica breaks down the major shifts in the new US guidance, including:The protein pivot: Why protein is taking center stage and what it means for your health.The plant-based omission: Why beans and legumes were left out of the new visuals despite the scientific evidence.The global gap: How the new US pyramid compares to the UK's Eatwell Guide and Canada's food plate.AHA vs. USDA: Why the American Heart Association is issuing its own "course correction" on salt and saturated fat.This episode will help you navigate these changes without losing sight of common-sense nutrition.Nutrition Diva is a Quick and Dirty Tips podcast, hosted by Monica Reinegal.New to Nutrition Diva? Check out our special Spotify playlist for a collection of the best episodes curated by our team and Monica herself! We've also curated some great playlists on specific episode topics including Staying Strong as We Age, Diabetes, Weight Loss That Lasts and Gut Health! Also, find a playlist of our bone health series, Stronger Bones at Every Age. Have a question for Nutrition Diva? Email: nutrition@quickanddirtytips.comFind Monica at wellnessworkshere.comDiscover more from Nutrition Diva:Facebook LinkedInNewsletterTranscripts available at QuickandDirtyTips.com. Hosted on Acast. See acast.com/privacy for more information.

En el PPP Extra de hoy:• Analizamos la renuncia del secretario de Desarrollo Económico Sebastián Negrón Reichard, nuestro querido “intern” y todo lo que sabemos — y sospechamos — sobre lo que realmente pasó detrás de la renuncia.• Y hablamos de qué podría pasar ahora dentro del gobierno y el impacto político del caso.En el chit chat:Knicks,Cangrejeros,y las fotos de JGo con Luisito Marie.

Diabetes can feel like one of the biggest and most overwhelming topics to study for NP boards. Between insulin types, medication classes, complications, and diagnostic criteria, it is easy to get lost in the details and spend hours studying without knowing what actually matters most.     In this episode, Alex and I walk through a practical diabetes review for NP boards and focus on the highest-yield concepts you should prioritize during your prep. This is not meant to be a complete deep dive into every diabetes medication or clinical nuance. Instead, we focus on the core concepts, common board-style presentations, medication side effects, and complications most important to understand for exams.                                   Get full show notes, transcript, and more information here: https://blog.npreviews.com/diabetes-review-for-np-boards               Follow us on Instagram: instagram.com/smnpreviewsofficial

Don Muchow has lived with Type 1 Diabetes for more than 50 years (@t1determined).But his story isn't just about Diabetes.At 42 years old, Don was overweight, struggling with his health, and already experiencing serious Diabetic complications before making a decision that completely changed the direction of his life.What started with exercise and small lifestyle changes eventually led to Ironman races, ultra-marathons, marathon swims, 200-mile cycling events, and even becoming the first and only known person with Type 1 Diabetes to run from Disneyland to Walt Disney World… covering 2,845 miles across America.In this episode, we talk about:Living with Type 1 Diabetes for over five decades.Overcoming complications later in life.Endurance training and blood sugar management.Fear around exercise and hypos.Aging with Type 1 Diabetes.Mindset, resilience, and consistency.What's actually possible with Diabetes long term.This is an incredibly honest, motivating, and practical conversation for anyone living with Type 1 Diabetes, especially those who feel like it may be “too late” to change their health.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

Sandi Peiffer has been happily married to her husband Corey for  39 yrs. She is a 61-year-old mother of 4 (ages 21-34) and grandmother of 3 (ages 6, 4, and 3 months… and #4 due in October!) who lives on the Atlantic coast of Florida. She is a retired homeschool mom of 26 years. She enjoys walking, resistance training, reading, crafting, cooking and spending time with her family. As an adult, Sandi has tried most of the diets we have all heard of… Weight Watchers, Susan Powter Stop the Insanity, TOPS, The Zone Diet, 40-30-30, Shake diets, Suzanne Somers “Somersize”, South Beach, Atkins, The Rosedale Diet, etc. Her real struggle with weight started when she went on an antidepressant for anxiety. Then the pounds really started to pack on. 120 lbs by the time it was all said and done. She found intermittent fasting after a diagnosis of Type 2. Diabetes with an A1C of 8.4 and a fasting glucose of 237. Starting IF in Dec. 2018, at 5'4” and 300 lbs. In this episode, she explains her IF journey over the past 7.5 yrs and the addition of peptides to her health journey. Her current weight is 170 lbs, her fasting glucose is 87, and her A1C is 4.8! At the end of the episode, she says she will mention some reference tools here:Youtube:Dr Tyna MooreThe DownsizedOn the PenDr Spencer Nadolsky Book:Weightless by Dr Rocio Salas-WhalenEnough: Your health, Your Weight and what it's like to be free by Ania M. Jastreboff, MD, Ph.D and Oprah WinfreyHow to connect with Graeme Join Graeme's Patreon and get accountability and support.www.patreon.com/thefastinghighwayWebsite to book a one-on-one call.www.thefastinghighway.com.To buy the book The Fasting Highway your local Amazon store, or any good online book seller. Disclaimer -The views in this podcast are those of the guest and host only and should not be taken as direct medical advice. Please consult your health professional before beginning any health plan.

 I just had my diabetes supplies changed by insurance without anyone even telling me.No notice. No consent. Just a different order showing up at my door.So I had to call in and figure it out myself.And instead of arguing, I used a few simple psychology-based tactics that completely changed how the conversation went… and I ended up not only fixing the issue, but getting extra supplies approved too.I broke down exactly what I did in this video — step by step — because this is something a lot of people living with diabetes quietly deal with, but don't really talk about. >> ENJOY!Join The Tribe: https://thewarriorstribe.comPurchase your copy of "The Blood Sugar Freedom Formula" book TODAY!https://www.amazon.com/dp/1964811880?psc=1&smid=ATVPDKIKX0DER&ref_=chk_typ_quicklook_imgToDpGrab your free ticket to this advanced T1D training here:https://diabetesinaction.comFree T1D Support Group Here: https://diabetesinaction.com/join-group-1---------Welcome to the Pardon My Pancreas podcast!! This show is all about REAL life with type 1 diabetes, understanding fluctuations, and how to stabilize your blood sugar for good. Your host is Matt Vande Vegte is a certified personal trainer, nutritionist, and type 1 diabetic whose biggest goal in life is to help people with diabetes around the world live their lives fearlessly. Looking for an online health coaching program to help you live your best life? Go to https://www.ftfwarrior.com to learn more about his program for diabetics only that is focused on helping you reach your goals while living a happier and healthier life. Join the Tribe today!This podcast is sponsored by FTF Warrior - An online health and fitness coaching company for type 1 diabetics dedicated to helping them master their blood sugars through any activity, exercise, or meal!https://www.ftfwarrior.comFollow Matt here:Instagram: https://www.instagram.com/ftfwarrior/Facebook: https://www.facebook.com/ftfwarrior/YouTube: https://www.youtube.com/c/ftfwarrior------------------------------------------------------Disclaimer: While we share our experiences with diabetes, nothing we discuss should be taken as medical advice. Please consult your doctor or medical professional for your health and diabetes management. 

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In this episode, Ken and Graham dive into one of the most overlooked parts of living with diabetes: the stories, beliefs, and identity patterns we create over time.What starts as a conversation about childhood experiences, sports, discipline, and self-worth evolves into a much deeper discussion about how people approach diabetes management—and why so many struggle with consistency, burnout, and decision-making.Ken opens up about growing up without a strong male role model, feeling like he had to figure everything out alone, and how those experiences shaped the way he approached school, sports, and eventually diabetes. The conversation connects these personal experiences directly back to Type 1 diabetes and the reality that most people naturally gravitate toward what feels easiest, most enjoyable, or least mentally exhausting.Ken and Graham also unpack:why people avoid pre-bolusing even when they know it helpsthe frustration with pumps and CGMs not being “perfect”how people pick and choose where they spend mental energyand why diabetes management has to fit into real life—not replace itThe episode finishes with a powerful hypothetical conversation:What if Ken had been diagnosed with diabetes in high school instead of adulthood?That leads into a raw and honest discussion around denial, immaturity, identity, athletics, mental health, and how different life experiences shape the way people respond to diabetes.This episode is deeply personal, reflective, and relatable for anyone who has ever struggled to balance diabetes with actually wanting to live life.

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In this episode, Ken and Graham dive into one of the biggest frustrations people living with Type 1 diabetes face: the gap between medical care and real-life diabetes management.The conversation starts with a powerful discussion around endocrinologists, insulin safety, and why most healthcare providers are forced to prioritize preventing dangerous lows over helping patients aggressively optimize blood sugars. Ken explains how fear of hypoglycemia, liability, and limitations within the healthcare system shape the guidance many people receive.From there, the episode evolves into a deep real-world conversation around:insulin pumps and automationdawn phenomenoninsulin resistance from stresslearning patterns and building “checklists”trusting Dexcom trend arrowsand how to actually troubleshoot blood sugar problems in real timeGraham also shares a brutally honest look into the mental frustration of waking up high from dawn phenomenon despite doing “everything right,” leading to a conversation many people with diabetes quietly relate to but rarely talk about openly.This episode blends education, emotional reality, and practical problem-solving into one of the most relatable diabetes conversations yet.

Abnehmspritzen werden manchmal als Lifestyle-Produkt abgetan. Dabei sind sie nichts anderes als eine medizinische Revolution. Zum ersten Mal hat die moderne Medizin ein wirksames Mittel gegen Adipositas. Und Studien zeigen: Sie haben noch jede Menge anderer Vorteile. Es erklärt der Universitäts-Professor und Endokrinologe Florian Kiefer.

Dr. Ian Lake has worked as a doctor in the NHS for nearly four decades, most of this time as a general practitioner. After being diagnosed with LADA Type 1 Diabetes at age 36 and managing it conventionally for 20 years, he adopted the low carb diet and has been following it for the past 10 years. He is a founding member of the Public Health Collaboration in the U.K. and has conducted several important research projects investigating the connection between low carb diets and human health. He has also worked with Dr. Tro and others to produce the Type 1 Consensus Statement. In this episode, Drs. Tro and Ian talk about… (00:00) Intro (03:30) The mental and physical health challenges faced by Type 1 Diabetics and how these challenges have traditionally been dealt with (13:44) Ketoacidosis, what insulin does, and modern methods/dietary reccomendations for controlling Type 1 Diabetes (25:45) How Dr. Lake's colleagues have responded to his ideas regarding Type 1 and ketogenic diets (38:00) Dr. Lake's new book, Shifting Gears, on the need to move from a glucose-centric view of Type 1 to a holistic, healthy human being perspective (50:23) Outro For more information, please see the links below. Thank you for listening! Links: Please consider supporting us on Patreon: https://www.lowcarbmd.com/ Resources Mentioned in this Episode: Dr. Ian Lake's last appearance on the LCMD Podcast: https://lowcarbmd.com/podcast/episode-368-dr-ian-lake/ Dr. Ian Lake: X: https://twitter.com/idlake Type1Keto: https://type1keto.com Type 1 Consensus Statement: https://journalofmetabolichealth.org/index.php/jmh/article/view/100 Case report: Ketogenic diet alleviated anxiety and depression associated with insulin-dependent diabetes management: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2024.1404842/full Shifting Gears (New Book): https://type1keto.com/product/shifting-gears-the-1000-mile-ride-that-changed-my-mindset-on-type-1-diabetes/ Dr. Brian Lenzkes:  Website: https://arizonametabolichealth.com/ Twitter: https://twitter.com/BrianLenzkes?ref_src=twsrc^google|twcamp^serp|twgr^author Dr. Tro Kalayjian:  Website: https://toward.health Twitter: https://twitter.com/DoctorTro IG: https://www.instagram.com/doctortro/ Toward Health App Join a growing community of individuals who are improving their metabolic health; together.  Get started at your own pace with a self-guided curriculum developed by Dr. Tro and his care team, community chat, weekly meetings, courses, challenges, message boards and more.  Apple: https://apps.apple.com/us/app/doctor-tro/id1588693888  Google: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.doctortro&hl=en_US&gl=US Learn more: https://toward.health/community/

Cutaneous findings in statin-induced necrotizing myopathy [article]ACD to diabetes devices (part 1) [article]Trichophyton indotineae - use itraconazole! [article]Eosinophilic pustular folliculitis in infants [article]Green beans for diaper rash in the NICU [article]Confocal in kids [article] Trichophyton indotineae laboratory resources:Fungus Testing Laboratory — UT Health San AntonioCenter for Medical Mycology — University Hospitals Cleveland Medical CenterMycology Laboratory — Wadsworth Center, NYS Department of HealthBako Diagnostics (BakoDx)Check out Luke's Urticaria CME experience! aaaaicsu.gathered.com/invite/KQe1wPZbJY Learn more about the U of U Dermatology ECHO model! physicians.utah.edu/echo/dermatology-primarycare Want to donate to the cause? Do so here!Donate to the podcast: ⁠uofuhealth.org/dermasphere⁠Check out our video content on YouTube:⁠www.youtube.com/@dermaspherepodcast⁠and VuMedi!: ⁠www.vumedi.com/channel/dermasphere/⁠The University of Utah's DermatologyECHO: ⁠⁠physicians.utah.edu/echo/dermatology-primarycare⁠ Connect with us!- Web: ⁠⁠dermaspherepodcast.com/⁠⁠ - Twitter: @⁠DermaspherePC⁠- Instagram: dermaspherepodcast- Facebook: ⁠www.facebook.com/DermaspherePodcast/⁠- Check out Luke and Michelle's other podcast, SkinCast! ⁠⁠healthcare.utah.edu/dermatology/skincast/⁠⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)- ⁠⁠www.levelex.com/games/top-derm⁠⁠ (A free dermatology game to learn more dermatology!

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-486 Overview: Optimizing diabetes management starts with choosing the right medication for the patient. Listen in as we discuss current prescribing recommendations, empowering you to confidently compare medication classes and select therapies that best fit individual patient needs—while prioritizing kidney protection to reduce the risk of long-term complications. Episode resource links: Jensen SK, Heide-Jørgensen U, Andersen IT, et al. SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes. JAMA Intern Med. Published online January 20, 2026. doi:10.1001/jamainternmed.2025.7409 Samson SL, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update. Endocr Pract. 2023;29(5):305-340. Guest: Jillian Joseph, MPAS, PA-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-486 Overview: Optimizing diabetes management starts with choosing the right medication for the patient. Listen in as we discuss current prescribing recommendations, empowering you to confidently compare medication classes and select therapies that best fit individual patient needs—while prioritizing kidney protection to reduce the risk of long-term complications. Episode resource links: Jensen SK, Heide-Jørgensen U, Andersen IT, et al. SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes. JAMA Intern Med. Published online January 20, 2026. doi:10.1001/jamainternmed.2025.7409 Samson SL, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update. Endocr Pract. 2023;29(5):305-340. Guest: Jillian Joseph, MPAS, PA-C   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

In this episode of the Your Diabetes Insider Podcast, I'm breaking down how I personally handle Memorial Day BBQs and cookouts without my blood sugars going completely off the rails. From grazing on appetizers, hidden carbs in "simple" foods, and delayed fat spikes, to figuring out insulin timing, pre-bolusing, and using activity to boost insulin sensitivity before you even show up - this is everything I wish I knew earlier. If BBQs usually turn into a CGM stress-fest for you, this will help you feel more prepared so you can actually enjoy the food, the people, and the day without constantly worrying about your blood sugar! Want the best blood sugars you've ever had while enjoying great food? Peep this: https://www.yourdiabetesinsider.com/coaching   RESOURCES: Download these FREE guides that will help you on your diabetes, nutrition, and exercise journey! https://www.yourdiabetesinsider.com/free-stuff LET'S TALK! Instagram: @yourdiabetesinsider Tiktok: @yourdiabetesinsider

This episode is brought to you by the⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Primal Tallow Soaps & Balms.⁠⁠⁠⁠⁠⁠⁠ Is it possible that our obsession with calories is blinding us to the true hormonal driver of obesity? In this episode, world-renowned metabolic researcher and insulin scientist Dr. Ben Bikman (PhD) joins us to deconstruct the "insulin-centric paradigm" of fat regulation. Drawing from his extensive laboratory research on the molecular mechanisms of metabolic disorders, Dr. Bikman explains why fat cells cannot store energy without the presence of insulin, regardless of caloric intake. From the competition of fuels in the Randall Cycle to the specific way carbohydrates and saturated fats interact with cellular signaling, this conversation provides the clarity needed to master your metabolism. Whether you are battling a weight-loss plateau or seeking root-cause insights into chronic disease, this discussion provides a clear path on how insulin affects metabolism, fat loss, and metabolic flexibility.In This Episode, We Reveal:The Insulin-Centric Paradigm: A scientific breakdown of why insulin is the primary gatekeeper of fat storage and how high levels prevent fat oxidation.The Mechanics of Fat Loss: Why "burning what you eat" is physiologically distinct from burning stored adipose tissue, and how to trigger the latter.The Randall Cycle & Fuel Prioritization: Understanding how the body chooses between glucose and fatty acids for fuel and the consequences of "metabolic inflexibility."Carbohydrates vs. Saturated Fats: A nuanced look at how different macronutrients influence insulin sensitivity and why the combination of carbs and fats can be a metabolic "perfect storm."Strategic Fasting & Refeeding: Why you should prioritize proteins and fats when breaking a fast to maintain a stable metabolic state.Identifying Clinical Markers: How to interpret common blood markers to identify insulin resistance long before it manifests as Type 2 Diabetes.

Can staying active really help reverse Type 2 diabetes? In this episode of The Heart of Innovation, Emmy Award-winning journalist Kym McNicholas and Dr. John Phillips sit down with multi-Emmy Award-winning CBS San Francisco Bay Area sports anchor Vern Glenn to talk about his personal journey reversing Type 2 diabetes — and why golf became far more than just a game. For Vern, the golf course became part of a larger commitment to movement, consistency, fitness, and long-term health. Walking the course, staying active, and building daily habits around exercise helped him take control of his blood sugar and inspire others to rethink what healthy living can look like. That mission is also what inspired the Vern Glenn Invitational Celebrity Golf Tournament. The event brings together former and current stars from the NFL, NBA, MLB, and beyond — many of whom continue participating in events like this not just for competition, but to stay active, connected, and healthy long after their professional playing careers end. Vern believes seeing athletes continue to prioritize fitness sends an important message: movement matters at every age. Whether it's walking 18 holes, staying social, or simply finding activities that keep you moving, the goal is building habits that support heart health, circulation, weight management, and better metabolic health over time. We also discuss the growing connection between exercise, obesity, cardiovascular disease, circulation, and diabetes prevention and reversal. ⛳ SIGN UP FOR THE VERN GLENN INVITATIONAL: https://www.vernglenninvitational.net/

Send us Fan MailHuman genetic variation in dietary fat metabolism and its implications for health & disease.TOPICS DISCUSSED:Linoleic Acid Rise: Linoleic acid now comprises 6-8% or more of energy in Western diets.Metabolic Pathways: Omega-6 linoleic acid converts to arachidonic acid and pro-inflammatory oxylipins; omega-3 ALA converts via shared enzymes to EPA/DHA with anti-inflammatory effects.FADS Genetic Variants: Ancestry-linked haplotypes in the FADS cluster create large “pipe” size differences, altering fatty acid by up to 40% between ancestral and derived versions.Population Differences: African ancestry populations often have high-conversion “big pipe” genotypes; Indigenous American ancestry populations have low-conversion “small pipe” genotypes; European ancestry comes with a mix of both.Omega-3 Deficiency: High linoleic intake suppresses EPA production, especially in small-pipe populations, contributing to hypertriglyceridemia and fatty liver in Mexican cohorts.Clinical Evidence: Reanalysis of VITAL trial showed 83% reduction in myocardial infarction with omega-3 supplementation in African Americans; Mexican data link low EPA to unique diabetes forms.Methodological Issues: Compositional data (from GC-FID measurements) versus absolute concentration measurements can flip relationships between linoleic acid and key biomarkers.ABOUT THE GUEST: Floyd Chilton PhD is Professor and Director of the Center for Precision Nutrition and Wellness at the University of Arizona. His research focuses on functional genomics, fatty acid metabolism, and precision nutrition, particularly how genetic ancestry influences responses to dietary fats.RELATED EPISODE:M&M 291: Omega Polyunsaturated Fats & Inflammation | Philip CalderSupport the showHealth Products by M&M Partners:AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models.OmegaQuant: At-home blood testing to see fatty acid profiles, including omega-3 fatty acids. Use link to see options and support M&M.SiPhox Health: Comprehensive, cost-effective bloodwork from the comfort of home. Use code TRIKOMES for 20% off.KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime)SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code 'nickjikomes' for 20% off.For all the ways you can support my efforts

Living with diabetes means paying attention to your health in ways others may never fully understand, and eye health is one of the most important parts of that journey. For Healthy Vision Month, this episode of Diabetes Day by Day features Sterling Glass sharing his personal diabetes and eye health journey, and why protecting vision is so important for people living with diabetes. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Lucia M. Novak, MSN, ANP-BC, BC-ADM, President and Founder of Diabesity LLC; Co-Executive Director, Diabetologist, and Obesity Management Specialist at Capital Health & Metabolic Center (part of Capital Diabetes & Endocrine Associates), Greater DC Area Sterling Glass, Diabetes Advocate living with type 1 diabetes and a member of the Blind Boys of Alabama Do you have questions or comments you'd like to share with Neil and Lucia? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day! Additional resources: Learn more about diabetes and eye health at diabetes.org/EyeHealth and enjoy the music of the Blind Boys of Alabama on their Spotify playlist. Read more about Sterling's journey.

Outside of pregnancy, guidelines emphasize diabetes self-management education and support to facilitate informed decision making, self-care behaviors, problem solving, and active collaboration with health care professionals. This includes, in those with good health literacy, the concept of patient-led self-titration of basal insulin results which has data that it improves glycemic management compared with clinician-led titration for type 2 diabetes among nonpregnant adults. But what about for GDM? Can patient's self manage their BASAL insulin? In this episode, we will review a new RCT published in April 2026 in the Green Journal on this very subject. As novel as this is, it is not the first to report on this as it was also published (retrospective study in the UK) in 2022. This is a novel approach to insulin in GDM but there are some questions that remain. Listen in for details.1. Boonpattharatthiti K, Wechkunanukul K, Mayang N, et al . Comparison of Insulin Titration Strategies for Glycemic Control in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.Diabetes Care. 2025. 2. Valent, Amy M. DO, MCR; Barbour, Linda A. MD, MSPH. Insulin Management for Gestational and Type 2 Diabetes in Pregnancy. Obstetrics & Gynecology 144(5):p 633-647, November 2024. | DOI: 10.1097/AOG.00000000000056403. Wang, Xiao-Yu MD; Gabbe, Steven MD; Landon, Mark B. MD; Venkatesh, Kartik K. MD, PhD et al. Patient-Led Insulin Titration for Glycemic Management With Gestational Diabetes Mellitus: A Randomized Controlled Trial. Obstetrics & Gynecology 147(4):p 501-509, April 2026. 4. McGovern AP, Hirwa KD, Wong AK, et al. Patient-led rapid titration of basal insulin in gestational diabetes is associated with improved glycaemic control and lower birthweight. Diabet Med. 2022;39:e14926. doi: 10.1111/dme.14926

Part 2 of Eoin's chat with Steven Cannady (@steven.cannady) to talk about the reality of living with Type 1 Diabetes for the past 21 years.Diagnosed at 13 years old, Steven shares the highs, lows, frustrations, and lessons that have shaped his journey, along with how running became something that gave him purpose, structure, and confidence.We also dive into the challenges of managing blood sugars while training for and completing 7 marathons, building Type 1 Diabetes Dash, and the mindset shifts that helped him stop seeing Diabetes as a limitation.A practical and honest conversation for anyone living with Type 1 Diabetes or trying to take better control of their health.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

Why are Black Americans still dying from preventable diseases at higher rates?In this episode of the Let's Be Clear Podcast, Pastor Jamal Bryant sits down with Dr. Yahki Rapha Elohim for a powerful conversation about Black health, healing, disease, and the growing wellness crisis in the Black community.Dr. Yahki explains why many symptoms people fear may actually be the body's natural healing response. The discussion covers diabetes, fibroids, gut health, mental health, plant based nutrition, and why so many preventable illnesses continue impacting Black Americans at higher rates.Pastor Jamal Bryant also challenges the church to think deeper about healing, prevention, and whether faith communities should play a bigger role in health education and wellness.This conversation is controversial, educational, and necessary.#LetsBeClearPodcast #JamalBryant #DrYahki #BlackHealth #NaturalHealing #GutHealth #PlantBased #MentalHealthThe Jamal Bryant Podcast "Let's Be Clear" is a conversation that rips off the bandaid to serious relevant issues in the community and around the country. It assesses the wounds and offers prescriptions of insight, understanding and direction. No punches are pulled, but jabs are thrown to hit right between the eyes of every listener. New Episode Drops every Thursday at 12pm est. at jamalbryant.orgJoin our Membership or Support our Channel to get access to perks:https://www.youtube.com/channel/UC1yEY95beOqcUz5TUqxqVgQ/joinFollow or Subscribe on our socials ~https://www.facebook.com/jamalbryantpodcasthttps://www.instagram.com/jamalbryantpodcast/https://www.tiktok.com/@jamalbryantpodcast https://twitter.com/jamalbryantpod

Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biology, ethical sourcing, and manufacturing profile of human trophoblast stem cells. In Part 2, the conversation shifts to the larger ambition: using those cells not just to treat disease, but to slow, stop, or reverse biological aging itself. The evidence starts with a striking finding from the National Institute on Aging, and it builds from there.Topics discussed:The science and ethics of sourcing stem cells from ectopic pregnancies (03:02)Differences in differentiation potential between very early-stage cells and traditional MSCs or iPSCs (05:09)The origins of the research focus, driven by NIH/NIA inquiry and lessons from Stanford parabiosis studies (07:27)Explanation of senescent cells, inflammation, and disease connections (08:51)Potential therapeutic scope, from neurodegeneration to autoimmune diseases, and systemic anti-inflammatory applications (09:26)Vision for aging prevention—possibility of maintaining young biological age through regular secretome therapy (10:21)Challenges and global differences in regulation, access, and clinical adoption (12:05)The realistic limits and potential for reversing versus preventing age-related damage (13:20)The future landscape of cell and gene therapy in medicine (14:20)Why more investment is needed in longevity science and therapeutics (16:25)Practical takeaways for listeners about improving healthspan and longevity today (18:07)Smart insight:Prevention is becoming the new frontier of medicine, shifting from treating disease to preserving long-term biological function. Yuta Lee highlights a future where proactive longevity strategies, from lifestyle choices to emerging biotech, could keep us healthier for longer and push toward “escape velocity” against aging.If you're interested in how we turn living biology into scalable, reliable, off-the-shelf therapies without losing control of the system, explore these episodes:Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver KraemerEpisodes 147 - 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari GargirEpisodes 179 - 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay DaviesEpisodes 211 - 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús ZurdoConnect with Yuta Lee:LinkedIn: www.linkedin.com/in/yuta10Accelerated Bio website: www.acceleratedbio.comNext:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

864.Does putting spinach in your smoothie cancel out the calcium? Will your morning cup of tea prevent you from absorbing iron? In this episode, Monica looks into the science of mineral absorption and explores the truth behind "anti-nutrients" like oxalates, tannins, and fiber.While certain compounds in food can bind to minerals—like the oxalates in spinach or tannins in tea—the body has built-in buffers to keep you healthy. In this episode, we discuss:The Spinach paradox: Why the calcium in greens isn't always bioavailable.Iron inhibitors: How coffee and tea affect iron levels (and how Vitamin C can help).The fiber myth: Why a high-fiber diet won't lead to mineral deficiencies.Fortified foods vs. supplements: Is calcium-fortified orange juice or soymilk better than a pill?The good news is the RDA (Recommended Dietary Allowance) already accounts for these interactions. Tune in to learn why a varied diet is your best defense and why you probably don't need to micromanage your meals to get the minerals you need.Nutrition Diva is a Quick and Dirty Tips podcast, hosted by Monica Reinegal.New to Nutrition Diva? Check out our special Spotify playlist for a collection of the best episodes curated by our team and Monica herself! We've also curated some great playlists on specific episode topics including Staying Strong as We Age, Diabetes, Weight Loss That Lasts and Gut Health! Also, find a playlist of our bone health series, Stronger Bones at Every Age. Have a question for Nutrition Diva? Email: nutrition@quickanddirtytips.comFind Monica at wellnessworkshere.comDiscover more from Nutrition Diva:Facebook LinkedInNewsletterTranscripts available at QuickandDirtyTips.com. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Eoin sits down with Steven Cannady (@steven.cannady) to talk about the reality of living with Type 1 Diabetes for the past 21 years.Diagnosed at 13 years old, Steven shares the highs, lows, frustrations, and lessons that have shaped his journey, along with how running became something that gave him purpose, structure, and confidence.We also dive into the challenges of managing blood sugars while training for and completing 7 marathons, building Type 1 Diabetes Dash, and the mindset shifts that helped him stop seeing Diabetes as a limitation.A practical and honest conversation for anyone living with Type 1 Diabetes or trying to take better control of their health.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

Lange, Michael www.deutschlandfunk.de, Forschung aktuell

Transforming healthcare delivery in resource-limited contexts around the world calls for compassionate, innovative solutions. Learn how The Luke Commission is bringing healthcare to the most isolated and underserved in Eswatini through a scalable model for advancing health equity.

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

Rafael Pepen was diagnosed with Type 1 diabetes at 17, right in the middle of rehearsing for his very first musical in the Dominican Republic. Without access to a CGM or carb counting education, he learned to manage largely on instinct. Years later, he moved to the US, pursued his dream of performing professionally, and eventually landed at Disney, where he now performs five high cardio shows a day.In this episode, Rafael sits down with Lauren to talk about what it actually looks like to manage T1D in a life that never slows down. He shares the months of burnout, panic attacks around lows, and constant roller coaster blood sugars that led him to seek coaching, and what shifted on the other side of that.WHAT WE COVER:What it was like to be diagnosed at 17 in the Dominican Republic with limited access to education, CGMs, or carb counting guidanceThe unique challenge of managing T1D across five high cardio shows a day and why it is a completely different beast from a traditional performance scheduleThe moment things started to unravel at Disney and what five months of daily lows, panic attacks, and burnout actually felt like from the insideWhat shifted when Rafael started working with a Risely coach and the tools that made the biggest difference for his day to day managementThe emotional side of T1D that most people never talk about, including what it felt like to cry during a low and the moment that started to changeWhat Rafael is still working toward and the one thing he wants most from his relationship with diabetes going forwardWHAT'S NEXT:

Is hypercortisolism the hidden culprit in a significant proportion of both difficult-to-treat diabetes and resistant hypertension? In part 4 of our special series, Dr. Neil Skolnik speaks with John Buse, MD to explore the effects of hypercortisolism, until just recently considered a vanishingly rare condition. This special episode is sponsored with support from Corcept. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John Buse, MD, The Verne S. Caviness Distinguished Professor and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine, a past president of medicine & science at the American Diabetes Association (ADA), and recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award Selected references: Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care April 2025 Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. Diabetes Care June 2025 MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension. HCP Live March 2026

Dr. Christine Marie, who along with her husband Tolga helped expose a man named, Samuel Bateman, who claimed to be the self-proclaimed prophet of a religious polygamous sect, known as the FLDS. Samuel Bateman claimed the group's leader, Warren Jeffs, had died while in prison, and he was the now the prophet. It is reported that Bateman formed his own group within the FLDS, where his male followers not only gave their adult wives to the him, but also their underage daughters, as young as 9 years old, to become Bateman's “wives,” and who he would sexually abuse. Dr.Phil will speak with Dr. Christine, who along with her husband Tolga, would earn the trust of Samuel Bateman and his followers, and be invited to spend one and a half years filming hundreds of hours of footage with them. Dr. Christine and Tolga would eventually begin secretly working with the FBI, while continuing to be embedded within the sect. Samuel Bateman would eventually be arrested and sentenced to 50 years in prison for the crimes he committed against his underage wives. Many of his adult male and female followers were also held to justice. Christine, Tolga, and their footage are featured in the Netflix 4 part documentary series, “Trust Me: The False Prophet,” which chronicles the rise and fall of Samuel Bateman, and is streaming now on Netflix.This episode is brought to you by:Don't wait! If you're on Medicare or will be soon, reach out to Chapter: Call: (352)-845-0659 or go to https://askchapter.org to learn about your Medicare options and get help finding ways to save money.Diabetes doesn't wait. And the cost of waiting can be devastating. But there is another option you need to know about. Learn more: https://drphildiabetes.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The world's okayest morning radio show offers you the entire broadcast from today with none of the music and limited commercials. Try to enjoy!

For most of human history, people went about their daily lives with a worm or two (or fifty) in their guts. Only in the past century, with pharmaceuticals and sanitation practices, have we made significant strides towards deworming the whole of humanity. And that's typically been thought of as a good thing, because having too many worms in your body can–quite literally–suck the life out of you. But is it possible to have… too few worms? Science wonders if deworming ourselves has actually led to an increase in certain chronic diseases. On this episode, we dive into Necator americanus, a.k.a. the American Hookworm, and its mysterious relationship with each of us. We trace the hookworm's 118-year journey from a demonized economic depressant, to its use as a desperate D.I.Y. immunosuppressant, to its potential as a medical treatment for a number of chronic diseases, everything from asthma to MS. We're bringing back two stories  from our 2009 episode Parasites plus new research on hookworms and autoimmune diseases, reported by Molly Webster Special thanks to Ethan Hein for the use of his remix of Mozart's Piano Concerto No. 21. Plus, Doris Pierce, and Dan and Alice Hadley. EPISODE CREDITS:  Reported by - Pat Walters and Molly Webster with help from - {{wREPORTERS}} Produced by - Matt Kielty with help from - Rebecca Rand Fact-checking by - Diane A. Kelly and Edited by  - Arianne Wack EPISODE CITATIONS: Articles -  Effect of experimental hookworm infection on insulin resistance in people at risk of type 2 diabetes (https://pubmed.ncbi.nlm.nih.gov/37495576/) by Giacomin PR et al. Nat Commun. 2023 Jul 26 Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)! Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today. Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org. Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Jockers dives into the top 5 protein-rich foods that help burn belly fat, stabilize blood sugar, and support overall metabolism. You'll learn which foods are essential for healing fatty liver and reducing cravings. Dr. Jockers highlights why protein is crucial for maintaining a healthy body and mind. Discover the power of red meat, eggs, fish, and other high-quality protein sources for optimal health. He also covers the role of collagen in healing your joints, skin, and gut health. These protein-packed foods can help fuel your body and promote fat-burning. You'll also hear about the common mistakes people make when choosing protein sources and how to avoid them. Plus, Dr. Jockers shares tips for incorporating the right amount of protein into every meal to maximize its benefits. In This Episode:  00:00 Collagen Protein Basics 00:20 Podcast Intro and What to Expect 04:18 Why Protein Burns Fat 05:34 Complete vs Incomplete Protein 07:14 Top Pick Grass Fed Red Meat 07:48 Egg Protein Benefits 08:33 Fish Protein and Omega 3s 10:44 Dairy Protein Options 11:58 Poultry Protein Pros and Cons 12:57 Collagen and Bone Broth Add On 14:39 Protein Summary and Vegetarian Tips 16:14 Final Wrap Up and Review Request   Unwind with Purality Health's KSM 66 Ashwagandha, clinically proven to reduce stress and improve overall health. Its advanced nano-absorption technology ensures you get this ancient herb's full benefits. Experience better sleep, enhanced memory, and a calmer mindset. Enjoy a special buy one, get one free offer now! Each order comes with a six-month satisfaction guarantee. Visit longevityroot.com/drj to claim your deal and start feeling less stressed today. Switch to Manukora Honey, packed with bioactive compounds like MGO to support your gut and immune health. This antioxidant-rich honey is the perfect replacement for processed sweeteners. Save up to 31% and get $25 in free gifts with the starter kit. Visit manukora.com/drjockers to claim your offer today!   "Protein isn't just about building muscle. It's one of the biggest keys to stabilizing blood sugar, reducing cravings, and burning belly fat." ~ Dr. Jockers   Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean TuneIn Radio     Resources: Visit longevityroot.com/drj for a buy one, get one free offer Visit manukora.com/drjockers to claim your offer today!   Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https:/www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/   If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/ 

In this episode, Monica breaks down the latest research on resveratrol and bone loss prevention. While the 2020 RESHAW study in Australia showed promising results for postmenopausal women, a more recent meta-analysis tells a different story. We separate the supplement hype from the evidence-based nutrition strategies that actually protect your skeleton as you age.Key Takeaways:The RESHAW Breakdown: Why 150 mg of resveratrol led to modest gains in hip and spine density—and why you'd need a lot of wine to replicate it.10-Year Fracture Risk: How to use the FRAX calculator to estimate your likelihood of a major fracture as part of your longevity strategy.The Meta-Analysis Reality Check: Why mashing up 10 human trials suggests resveratrol might not be the "magic pill" for bone density.The "Healthspan" Levers: Why protein timing, Fibermaxxing, and Vitamin K remain the gold standards for sarcopenia prevention and bone strength.Resources:FRAX Calculator: 10-year fracture risk toolEpisode 734: Closing the calcium gap safely.Nutrition Diva is a Quick and Dirty Tips podcast, hosted by Monica Reinegal.New to Nutrition Diva? Check out our special Spotify playlist for a collection of the best episodes curated by our team and Monica herself! We've also curated some great playlists on specific episode topics including Staying Strong as We Age, Diabetes, Weight Loss That Lasts and Gut Health! Also, find a playlist of our bone health series, Stronger Bones at Every Age. Have a question for Nutrition Diva? Email: nutrition@quickanddirtytips.comFind Monica at wellnessworkshere.comDiscover more from Nutrition Diva:Facebook LinkedInNewsletterTranscripts available at QuickandDirtyTips.com. Hosted on Acast. See acast.com/privacy for more information.